Here is something to watch that has nothing to do with medical marijuana. Phase 3 trials will be reported in July 2017 regarding verubecestat, a Merck drug that has shown preliminary results in slowing down Alzheimers changes in the brain. Here’s the Guardian article (you don’t read the Guardian? You should. )
The drug, a BACE1 blocker, has been shown to slow the production of beta-amyloid plaques in the brains of Alzheimers patients. The current trials are designed to see if cognitive decline can be stopped. This is very exciting stuff that we should all keep an eye on.